WHEL-C-019 · Emerging evidence · 3.8/10

TANEZUMAB for endometriosis

Tanezumab, an anti-NGF (beta-nerve growth factor) antibody, is annotated as a Phase 2 clinical candidate for endometriosis.

Origin · ApprovedPathway · 505(b)(2) · existing active ingredient, new indicationEvidence arm · Pathway insightsEvidence supports

How to read thisThe summary above and the proposed mechanism are generated by the model from the sources it ingested, and are written as the model’s reasoning rather than established fact. Any figure quoted from MATRIX is a model-derived association score, not a clinical measurement. How far the published record backs this pair is carried by the score’s own rigor dimension and traced to verbatim sources at the foot of the page.

Hypothesized mechanism

By inhibiting nerve growth factor (beta-NGF), tanezumab may reduce nociceptive sensitization and pain associated with endometriosis.

This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.

How the score was reached, for this pair

The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 3.8 of 10 overall, a emerging reading, from a pathway rated emerging in strength.

The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.

Pathway arm · anchors the headline3.8 / 10 · Emerging

Scored for women. Female representation not stated — applicability to women uncertain (flagged for full text). (band F4, ×0.75).

Corroboration

Only a single source (Open Targets) is cited, providing one line of evidence (drug-target-indication annotation). No independent mechanistic lines converge in the verified claims.

0 / 2

Rigor

The claim reflects a clinical development annotation (PHASE_2 candidate for endometriosis), which implies human-relevant context, but no actual study data, model, or outcome is provided in the claims. The evidence is a database annotation rather than a reported experiment.

1 / 2

Specificity

Tanezumab is described as a beta-nerve growth factor inhibitor acting on the specific target NGF, a highly specific monoclonal antibody mechanism. The drug-target relationship is clearly and precisely stated.

2 / 2

Plausibility

NGF inhibition is mechanistically relevant to pain pathways in endometriosis, supporting target-phenotype fit, and the drug is listed as a PHASE_2 endometriosis candidate. However, the claim provides only the annotation without phenotypic evidence linking NGF inhibition to endometriosis outcomes.

1 / 2

Consistency

There is only one positive claim, so there are no conflicting signals, but also no convergence of multiple signals to assess directional consistency. The single annotation is internally coherent.

1 / 2

How the scoring rubric works, in general →

Layers not covered for this pair

Sex-specific pharmacokineticsNone on file

Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.

More on the sex-specific pharmacokinetics layer and its sources →

Cycle-phase dependenceNone on file

Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.

More on the cycle-phase layer and its sources →

Source evidence · what the pipeline ingested

These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).

Every source below belongs to this signal’s evidence arm, Pathway insights. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.

1Per Open Targets (retrieved 2026-06-16), TANEZUMAB (a Antibody) is a clinical candidate for endometriosis (maximum clinical stage PHASE_2); its mechanism of action is Beta-nerve growth factor inhibitor on target nerve growth factor. Open Targets · mechanistic ↗

These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.

The primary sources and pipelines this evidence is drawn from →

← Back to the full index